 |
Relative risk 63% higher in current users – but absolute risk fairly low and falls after 6 months Related items from OnMedica Clinical trials needed on safety of testosterone Statins may slow prostate cancer progression in advanced disease Testosterone levels recover after obesity surgery Testosterone for menopausal women Extending anticoagulation duration cuts risk of VTE recurrence |
Thursday, 1 December 2016
VTE risk raised in first 3-6 months of testosterone treatment
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment